Bear discusses studies adding treatments to chemotherapy in order to increase the pathological complete response (pCR) rate and the difficulties of translating those benefits into better overall survival (OS) rates for patients with breast cancer.
Harry Bear, MD, PhD
Advertisement
Articles by Harry Bear, MD, PhD
Advertisement
Latest Updated Articles
Dr. Harry Bear on Translating Pathological Complete Response to OS BenefitsPublished: March 3rd 2016 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5
